We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Expanding Screening and Biomarker Testing Drive Cancer Diagnostics Market Growth

By LabMedica International staff writers
Posted on 20 Oct 2026

Cancer diagnostics encompasses imaging, tissue pathology, laboratory testing, and molecular technologies used to detect, confirm, characterize, and monitor cancer. More...

The global cancer diagnostics market is projected to grow from USD 29.3 billion in 2026 to USD 41.5 billion by 2031, representing a compound annual growth rate (CAGR) of 7.2%. These are the latest findings of Wissen Research (Sheridan, WY, USA), a market research and consulting firm.

Market growth is being driven by the rising global cancer burden, expanding screening programs, and increasing demand for earlier and more accurate disease detection. Approximately 20 million new cancer cases and 9.7 million cancer deaths were recorded worldwide in 2022, while annual new cases are expected to exceed 35 million by 2050. This growing burden is increasing demand for screening, diagnosis, staging, molecular characterization, treatment selection, and disease monitoring.

Cancer diagnosis is also evolving from a process centered primarily on medical imaging and microscopic tissue examination into a layered approach incorporating molecular and genomic testing, liquid biopsy, digital pathology, and artificial intelligence (AI). Next-generation sequencing-based comprehensive genomic profiling enables laboratories to evaluate multiple biomarkers from a single sample, while companion diagnostics help identify patients most likely to benefit from specific targeted therapies.

Liquid biopsy is gaining importance because it can detect tumor cells or tumor-derived DNA in blood and other body fluids without requiring repeated tissue biopsies. These tests can support diagnosis, treatment selection, response monitoring, and detection of recurrence. However, tissue-based diagnostics remain essential, as liquid biopsy and multi-cancer detection tests continue to face challenges involving sensitivity, specificity, clinical validation, and demonstrated utility in improving patient outcomes.

Based on product type, in vitro diagnostic testing held the largest share of the cancer diagnostics market in 2025. This category includes kits and reagents, PCR and next-generation sequencing instruments, in situ hybridization, immunohistochemistry, immunoassays, and flow cytometry. Its leading position reflects the extensive use of laboratory testing for confirming malignancy, evaluating biomarkers, characterizing tumors, and guiding treatment decisions.

By application, diagnosis and disease characterization accounted for the largest market share in 2025. Molecular and genomic tests can identify mutations, gene fusions, biomarker expression, microsatellite instability, and mismatch repair status, providing information that supports tumor classification and therapy selection. At the same time, AI-enabled imaging and digital pathology systems are being developed to assist with lesion detection, classification, workflow automation, and analysis of increasingly complex diagnostic data.

The market has also seen continued investment in pathology, imaging, and AI-enabled diagnostic workflows. In September 2026, Danaher subsidiary Leica Biosystems completed its acquisition of StatLab Medical Products, expanding its anatomic pathology capabilities across specimen collection, preparation, staining, digital imaging, and AI-assisted diagnosis. Siemens Healthineers and Vanderbilt Health entered a USD 87 million partnership in July 2026 to modernize diagnostic imaging and radiation oncology, while Roche agreed in May 2026 to acquire PathAI for up to USD 1.05 billion to strengthen its digital pathology and AI capabilities.

Geographically, North America held the largest share of the cancer diagnostics market in 2025, supported by established screening programs, advanced healthcare infrastructure, sophisticated imaging and laboratory technologies, precision oncology programs, and high healthcare expenditure. Asia Pacific is expected to register the fastest growth as the region’s cancer burden increases and investment expands in hospitals, diagnostic laboratories, screening programs, molecular testing, digital diagnostics, and advanced imaging.

Related Links
Wissen Research


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Electrolyte Analyzer
BKE-B
Gold Member
Aspiration System
VACUSAFE
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image Credit: Shutterstock

Lung Cancer Atlas Reveals Cellular Patterns Associated With Patient Prognosis

Lung cancer is a leading cause of cancer-related death worldwide and is characterized by substantial cellular heterogeneity. Even within a single tumor, cancer cells can vary in aggressiveness, while immune,... Read more

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: Malaria is caused by Plasmodium parasites, primarily transmitted through the bites of infected female Anopheles mosquitoes (Image Credit: Adobe Stock)

Complete Malaria Genomes Could Improve Species Identification and Surveillance

Malaria remains a major global health challenge, with an estimated 282 million cases and 610,000 deaths worldwide in 2024. Although most research has focused on Plasmodium falciparum, Plasmodium ovale... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.